Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.74 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665760 | 1.00 | CHRNB2 (0.74) | CHRNB2CHRNA4MEN1NPC1TP53 | |
| SCHEMBL1980777 | 0.98 | CHRNB2 (0.77) | CHRNB2CHRNA4MEN1NPC1TP53 | |
| SCHEMBL30665753 | 0.94 | CHRNB2 (0.77) | CHRNB2CHRNA4MEN1NPC1TP53 | |
| SCHEMBL2067959 | 0.94 | CHRNB2 (0.77) | CHRNB2CHRNA4MEN1NPC1TP53 | |
| SCHEMBL5654646 | 0.85 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL3067510 | 0.83 | CHRNB2 (0.94) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL30066253 | 0.81 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL3707068 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNA4MEN1NPC1TP53 | |
| SCHEMBL2257074 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3067811 | 0.81 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069650-A | Alkynyl compound, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-11-17 | — | — | CN | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| CN-104903320-B | Nitrogen-containing heterocycle compound or its salt | 富士胶片株式会社 | 2018-11-13 | — | — | CN | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| WO-2018075858-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | SAMUMED, LLC (US) | 2018-04-26 | — | — | WO | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| CN-102958918-B | Novel tobacco amide derivatives or its salt | FUJIFILM CORP. (JP) | 2015-12-09 | — | — | CN | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | AC IMMUNE, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-0739342-B1 | PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-5723477-A | CENTRAL NERVOUS SYSTEM OR AUTONOMIC NERVOUS SYSTEM, CARDIOVASCULAR DISORDERS, GASTROINTESTINAL DISORDERS OR DRUG ABUSE | SIBIA NEUROSCIENCES, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5705512-A | COGNITION ACTIVATORS USING PYRROLIDINE PYRIDINE | SIBIA NEUROSCIENCES, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5703100-A | PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS; GASTROINTESTINAL DISORDERS; CARDIOVASCULAR DISORDERS | SIBIA NEUROSCIENCES, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5677459-A | PYRIDINE COMPOUNDS | SIBIA NEUROSCIENCES, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5594011-A | Modulators of acetylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | APP, PSEN1, PSEN2 | CHRNB2 113/4885CHRNA4 425/4885MEN1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.